Immunitybio Inc (NASDAQ:IBRX) — Market Cap & Net Worth
Market Cap & Net Worth: Immunitybio Inc (IBRX)
Immunitybio Inc (NASDAQ:IBRX) has a market capitalization of $5.96 Billion ($5.96 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3248 globally and #1135 in its home market, demonstrating a -6.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunitybio Inc's stock price $6.72 by its total outstanding shares 984965179 (984.97 Million). Review how much debt does Immunitybio Inc carry to assess the company's total debt and financial obligations.
Immunitybio Inc Market Cap History: 2015 to 2026
Immunitybio Inc's market capitalization history from 2015 to 2026. Data shows change from $17.07 Billion to $6.62 Billion (-5.76% CAGR).
Index Memberships
Immunitybio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.24% | #74 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #357 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.35% | #50 of 263 |
Weight: Immunitybio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunitybio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunitybio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
171.01x
Immunitybio Inc's market cap is 171.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $17.07 Billion | $236.00K | -$236.88 Million | 72328.16x | N/A |
| 2016 | $5.63 Billion | $44.00K | -$120.81 Million | 128045.47x | N/A |
| 2017 | $4.42 Billion | $45.00K | -$96.42 Million | 98277.64x | N/A |
| 2018 | $1.14 Billion | $47.00K | -$96.23 Million | 24309.78x | N/A |
| 2019 | $3.73 Billion | $43.00K | -$65.79 Million | 86814.37x | N/A |
| 2020 | $13.13 Billion | $605.00K | -$221.85 Million | 21701.79x | N/A |
| 2021 | $5.99 Billion | $934.00K | -$346.79 Million | 6411.76x | N/A |
| 2022 | $4.99 Billion | $240.00K | -$416.57 Million | 20807.39x | N/A |
| 2023 | $4.94 Billion | $622.00K | -$583.20 Million | 7949.40x | N/A |
| 2024 | $2.52 Billion | $14.74 Million | -$413.56 Million | 171.01x | N/A |
Competitor Companies of IBRX by Market Capitalization
Companies near Immunitybio Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Immunitybio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Immunitybio Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Immunitybio Inc's market cap moved from $17.07 Billion to $ 6.62 Billion, with a yearly change of -5.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.62 Billion | +239.39% |
| 2025 | $1.95 Billion | -22.66% |
| 2024 | $2.52 Billion | -49.00% |
| 2023 | $4.94 Billion | -0.99% |
| 2022 | $4.99 Billion | -16.61% |
| 2021 | $5.99 Billion | -54.39% |
| 2020 | $13.13 Billion | +251.72% |
| 2019 | $3.73 Billion | +226.72% |
| 2018 | $1.14 Billion | -74.16% |
| 2017 | $4.42 Billion | -21.50% |
| 2016 | $5.63 Billion | -66.99% |
| 2015 | $17.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Immunitybio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.96 Billion USD |
| MoneyControl | $5.96 Billion USD |
| MarketWatch | $5.96 Billion USD |
| marketcap.company | $5.96 Billion USD |
| Reuters | $5.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more